Helus Pharma Inc (HELP)
HELPNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$9.04
+0.1800 (+2.03%) today
At the close, Nov 12, 4:00 PM ET. Pre-market $9.05 +2.14%
- Market cap
- $661.21m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.76 to $15.15
- Average volume
- –
- Previous close
- $8.86
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $41.71, +361.4% from here
Earnings
next estimate $-0.6700Next report
Sep 2025
-87.8%
Dec 2025
-35.9%
Jun 2026
-13.8%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- Cybin Expects Key Phase III Depression Trial Results This QuarterMarketBeat · 3 days ago
- Cybin Inc. Announces Co-Founders Eric So and Paul Glavine Transition from Executive RolesFintel · 7 days ago
- Cybin Inc. Announces Co-Founders' Transition from Executive Leadership on October 27, 2026Fintel · Oct 27, 2026
- Helus Pharma, Formerly Cybin Inc., Highlights Clinical Program Advancements at October 21, 2026 Investor PresentationFintel · Oct 22, 2026
- Cybin Eyes Q4 Phase III Depression Data as Anxiety Program AdvancesMarketBeat · Oct 21, 2026
- Cybin Inc. (HELP) Upgraded to Buy: What Does It Mean for the Stock?Zacks · Oct 20, 2026
- Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major DepressionMarketBeat · Sep 24, 2026
- Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member BoardMarketBeat · Sep 22, 2026
The company
Helus Pharma is a clinical stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The Company operates in Canada, the United States, the United Kingdom, and Ireland.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- helus.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.